Skip to contentI
Interpace Biosciences, Inc.
I
IDXGInterpace Biosciences, Inc. Q2 2018 · 10-Q
Revenue$5.50M$5.50M+42.7% vs Q2 2017 Net Income-$2.00M-$2.00MN/M vs Q2 2017 EPS Diluted-$0.07-$0.07N/M vs Q2 2017 Gross Profit$3,254,000+64.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Interpace Biosciences, Inc. · CIK 1054102 · Engraved from SEC EDGAR
Operating Cash Flowderived-$2,533,000N/M Free Cash Flowderived-$2,552,000— Margins · derivedGross margin59.2%+7.9 pt vs Q2 2017
Operating margin-34.5%+58.8 pt vs Q2 2017
Net margin-36.4%+129.4 pt vs Q2 2017
ended Jun 30, 2018 · filed Aug 9, 2018 · 40 d after period end